



JUN 10 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

## Complete if Known

Application Number	10/559543
Filing Date	December 2, 2005
First Named Inventor	Russell Rother
Art Unit	N/A
Examiner Name	Not Yet Assigned

Attorney Docket Number ALXN-P01-106

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/R.S./	AA	6,491,916	12-10-2002	Bluestone et al.	
/R.S./	AB	2003/0100741	05-29-2003	Muller et al.	
/R.S./	AC	5,527,713	06-18-1996	Bolton et al.	
/R.S./	AD	6,352,694	03-05-2002	June et al.	
R.S./	AE	6,406,696	06-18-2002	Bluestone	
/R.S./	AF	6,143,297	11-07-2000	Bluestone	
/R.S./	AG	6,113,901	09-05-2000	Bluestone	
/R.S./	AH	5,929,212	07-27-1999	Jolliffe et al.	
/R.S./	AI	5,834,597	11-10-1998	Tso et al.	
/R.S./	AJ	5,316,763	05-31-1994	Ochoa et al.	
/R.S./	AK	5,821,337	10-13-1998	Carter et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> -Number-Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
/R.S./	BA	WO 02/069232	09-06-2002	Merck Patent GMBH et al.		
/R.S./	BB	WO 98/52976	11-26-1998	Biovation Limited et al.		
/R.S./	BC	WO 91/09967	07-11-1991	Celltech Limited et al.		
/R.S./	BD	WO 00/34317	06-15-2000	Biovation Limited et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*CITE NO.: The cite number(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IWF. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/R.S./	CA	Jolliffe, "Humanized Antibodies: Enhancing Therapeutic Utility Through Antibody Engineering," <i>International Reviews of Immunology</i> , 10:241-250 (1993).	
	CB	GenBank Accession No. D82081	
	CC	GenBank Accession No. A22250	
	CD	GenBank Accession No. A22264	
/R.S./	CE	Carpenter, et al. "Non-Fc Receptor Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells," <i>The Journal of Immunology</i> , 165:6205-6213(2000).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Ronald Schwadron/	Date Considered	12/02/2008
--------------------	--------------------	-----------------	------------

10054021\_1

References that were not considered had incomplete citations.



JUN 16 2006

PTO/SB/02 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Application No. (if known): 10/559543

Attorney Docket No.: ALXN-P01-106

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on 6/12/06 Date

  
\_\_\_\_\_  
Signature

Jennifer Tardiff

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 951-7000

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (2 pages)  
IDS (Citation) by Applicant (20 References) (1 page)  
Copies of references BA-BD and CA-CE  
This postcard receipt